CONTEXT: A diagnosis of Addison's disease means lifelong dependence on daily glucocorticoid and mineralocorticoid therapy and is associated with increased morbidity and mortality as well as a risk of unexpected adrenal crisis. OBJECTIVE: The objective of the study was to determine whether immunomodulatory therapy at an early stage of autoimmune Addison's disease could lead to preservation or improvement in adrenal steroidogenesis. DESIGN AND INTERVENTION: This was an open-label, pilot study of B lymphocyte depletion therapy in new-onset idiopathic primary adrenal failure. Doses of iv rituximab (1 g) were given on d 1 and 15, after pretreatment with 125 mg iv methylprednisolone. PATIENTS AND MAIN OUTCOME MEASURES: Six patients (aged 17-47 yr; four females) were treated within 4 wk of the first diagnosis of idiopathic primary adrenal failure. Dynamic testing of adrenal function was performed every 3 months for at least 12 months. RESULTS: Serum cortisol levels declined rapidly and were less than 100 nmol/liter (3.6 μg/dl) in all patients by 3 months after B lymphocyte depletion. Serum cortisol and aldosterone concentrations remained low in five of the six patients throughout the follow-up period. However, a single patient had sustained improvement in both serum cortisol [peak 434 nmol/liter (15.7 μg/dl)] and aldosterone [peak 434 pmol/liter (15.7 ng/dl)] secretion. This patient was able to discontinue steroid medications 15 months after therapy and remains well, with improving serum cortisol levels 27 months after therapy. CONCLUSION: New-onset autoimmune Addison's disease should be considered as a potentially reversible condition in some patients. Future studies of immunomodulation in autoimmune Addison's disease may be warranted.
CONTEXT: A diagnosis of Addison's disease means lifelong dependence on daily glucocorticoid and mineralocorticoid therapy and is associated with increased morbidity and mortality as well as a risk of unexpected adrenal crisis. OBJECTIVE: The objective of the study was to determine whether immunomodulatory therapy at an early stage of autoimmune Addison's disease could lead to preservation or improvement in adrenal steroidogenesis. DESIGN AND INTERVENTION: This was an open-label, pilot study of B lymphocyte depletion therapy in new-onset idiopathic primary adrenal failure. Doses of iv rituximab (1 g) were given on d 1 and 15, after pretreatment with 125 mg iv methylprednisolone. PATIENTS AND MAIN OUTCOME MEASURES: Six patients (aged 17-47 yr; four females) were treated within 4 wk of the first diagnosis of idiopathic primary adrenal failure. Dynamic testing of adrenal function was performed every 3 months for at least 12 months. RESULTS: Serum cortisol levels declined rapidly and were less than 100 nmol/liter (3.6 μg/dl) in all patients by 3 months after B lymphocyte depletion. Serum cortisol and aldosterone concentrations remained low in five of the six patients throughout the follow-up period. However, a single patient had sustained improvement in both serum cortisol [peak 434 nmol/liter (15.7 μg/dl)] and aldosterone [peak 434 pmol/liter (15.7 ng/dl)] secretion. This patient was able to discontinue steroid medications 15 months after therapy and remains well, with improving serum cortisol levels 27 months after therapy. CONCLUSION: New-onset autoimmune Addison's disease should be considered as a potentially reversible condition in some patients. Future studies of immunomodulation in autoimmune Addison's disease may be warranted.
Authors: A De Bellis A; A Falorni; S Laureti; S Perrino; C Coronella; F Forini; E Bizzarro; A Bizzarro; G Abbate; A Bellastella Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: H Tanaka; M S Perez; M Powell; J F Sanders; J Sawicka; S Chen; L Prentice; T Asawa; C Betterle; M Volpato; B R Smith; J Furmaniak Journal: J Clin Endocrinol Metab Date: 1997-05 Impact factor: 5.958
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Taylor M Triolo; Priyaanka Nanduri; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: Mark D Pescovitz; Carla J Greenbaum; Heidi Krause-Steinrauf; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Paula F McGee; Antoinette M Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane Wherrett; Darrell M Wilson; John M Lachin; Jay S Skyler Journal: N Engl J Med Date: 2009-11-26 Impact factor: 91.245
Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245
Authors: Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy Journal: J Clin Endocrinol Metab Date: 2016-01-13 Impact factor: 5.958
Authors: Catherine Napier; Kathleen Allinson; Earn H Gan; Anna L Mitchell; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Simon H S Pearce Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958
Authors: Catherine Napier; Earn H Gan; Anna L Mitchell; Lorna C Gilligan; D Aled Rees; Carla Moran; Krishna Chatterjee; Bijay Vaidya; R Andrew James; Yaasir Mamoojee; Simon Ashwell; Wiebke Arlt; Simon H S Pearce Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958